• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Belviq Revenue 1Q 2016


<



























Has the genius Ciriello figured it out yet?
Hard to believe that numbnut is still around..

Oh wait... O'Brien and Coats coasted along as Eisai was sliding downhill fast in every division. All the while Japan kept whistling past the graveyard.

Conclusion, don't expect FC to be shown the door anytime soon.